Treatment effects of Endoscopic Cardiac Mucosal Resection (CMR) for refractory gastroesophageal reflux disease (GERD): a prospective study

Treatment effects of Endoscopic Cardiac Mucosal Resection (CMR) for refractory gastroesophageal reflux disease (GERD): a prospective study - Endoscopic Cardiac Mucosal Resection (CMR) for refractory gastroesophageal reflux disease (GERD)

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013565

Enrollment

Registered

2014-03-30

Start date

2012-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractory gastroesophageal reflux disease

Interventions

Medication with endoscopic cardiac mucosal resection for refractory gastroesophageal reflux disease. Medication without endoscopic cardiac mucosal resection for refractory gastroesophageal reflux dise

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) histologically proven adenocarcinoma. (2) age 20-80 years. (3) sufficient organ function. (4) Performance status(ECOG) 0 to 1. (4) Having written informed consent

Exclusion criteria

Exclusion criteria: (1) Any patients judged to be unfit to participate in the study, by the investigator.

Design outcomes

Primary

Measure	Time frame
Treatment efficacy (subjective and objective symptom)	—

Secondary

Measure	Time frame
Treatment completion rate Incidence of complication rate Recurrence rate	—

Countries

Japan

Contacts

Public ContactHaruhiro Inoue, MD, PhD

Showa University Koto-Toyosu Hospital Digestive Disease Center

haruinoue777@yahoo.co.jp03-6204-6000

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026